Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial.

Paula DakinAlan J KivitzJoseph S Gimbel Nebojsa SkrepnikStephen J DiMartinoChetachi A EmeremniHaitao GaoNeil StahlDavid M WeinreichGeorge D YancopoulosGregory P Geba

Published in: Annals of the rheumatic diseases (2020)

Fasinumab highest doses, but not lower dose, improved both CLBP pain and function. Most joint AEs occurred in pOA patients, consistent with earlier findings in symptomatic OA. Further study is needed of patients with CLBP with and without pOA to determine optimal benefit-risk.

Keyphrases

clinical trial
phase ii
open label
double blind
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
chronic pain
study protocol
phase iii
placebo controlled
pain management
randomized controlled trial
neuropathic pain
spinal cord